IL6 and rheumatoid arthritis: IL-6 inhibitors, e.g. tocilizumab and sarilumab, and anti-TNF adalimumab, are known to have analgesic efficacy with emerging evidence that they confer a dual benefit in RA patients, treating both inflammatory disease and non-inflammatory (nociplastic) pain [128, 129].